Belite Bio, Inc American Depositary Shares

Belite Bio has priced a public offering of 2,272,727 American Depositary Shares at $154.00 per share, expecting to raise approximately $350 million to fund commercialization preparation, pipeline development, and general corporate purposes.

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.

The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Over the past 3 months, 4 analysts have published their opinion on Belite Bio (NASDAQ:BLTE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

The clinical-stage biotech company bounced back from a 52-week low late last week.